Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T18:01:02.597Z.
Calculation as of: 2026-10-06T18:01:02.597Z.
Quote observation: 2026-10-06T18:00:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a39ca6935a26d8aa5af55aa8ea7db8fcfa7d32011c972ec9cce8dd9481767f6
EARNINGS YIELD
N/A
BridgeBio Oncology Therapeutics Inc.
Market Cap
$283.11M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$283.11M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$281.92M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$285.26M
Earnings Yield
N/A
TTM Avg
17.53%
3Y Avg
17.53%
5Y Avg
17.53%
Market Cap
$291.39M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $283.11M | N/A | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $283.11M | N/A | N/A | N/A | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.92M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.26M | N/A | 17.53% | 17.53% | 17.53% |
| Sagimet Biosciences Inc. (SGMT)vs › | $285.74M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $280.29M | N/A | 3.82% | 3.82% | 3.82% |
| Standard BioTools Inc. (LAB)vs › | $287.49M | N/A | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $291.39M | N/A | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $272.01M | N/A | N/A | N/A | N/A |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $270.31M | N/A | 4.11% | 3.31% | 6.16% |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
